Continuing Education. Please enter valid email address. Login Register. Update Profile Logout. Cardiovascular Health. Chronic Kidney Disease. Mental Health. Psoriatic Arthritis. Vitamins and Supplements. Specialty Pharmacy.
Register for a free account
Alternative Date. General Industrial OEM. Off-Highway Vehicles.
pharmacist or repackager to place a beyond-use date on this package. The. USP provides guidelines for the beyond-use dating of repackaged unit-.
Extending pharmacy beyond-use dates can be costly and time consuming. There are a number of factors to consider, including finding a quality trusted lab partner. Omnicell is taking the guesswork out of the sterile compounding IV beyond-use dating process and making it easier for our customers with the Formulary Tool Kit. Formulary Tool Kit is in partnership with Analytical Research Laboratories ARL , a contract research laboratory serving the pharmaceutical and compounding pharmacy industries since Omnicell customers around the world are responding to industry challenges by initiating change management and digital transformation strategies.
On day one, these organizations experience the benefits of their journey to the autonomous pharmacy. This free service collects, aggregates, and translates data into valuable insights for improving your pharmacy operations. Leverage the safety of on-site automated IV compounding technology with the benefits of expert insourcing. Jump to Overview Benefits Details Product Brochure. Formulary Tool Kit. Request more information. Accelerate Your Insourcing Initiatives and Return on Investment Extending pharmacy beyond-use dates can be costly and time consuming.
Extending the Beyond-Use Dates for Sterile Preparations
Beyond-use Date: Establishment and Maintenance. This includes the issue of increased waste and the cost associated with it. Many facilities opined that this would cause irreparable harm to both the care of the patient and the fiscal well-being of the institution. One of the first issues dealt with was the terminology. Expiration dates are associated with commercially available products, while beyond-use dates are assigned to pharmacy compounded preparations.
Special Handling, Packaging, Labeling, and Beyond Use Dating. Latest version. A. The pharmacy shall make available special handling and packaging.
Beyond-use dates for CSPs are rarely based on preparation-specific chemical assay results, which are used with the Arrhenius equation to determine expiration dates see General Notices and Requirements for manufactured products. The majority of CSPs are aqueous solutions in which hydrolysis of dissolved ingredients is the most common chemical degradation reaction. The extent of hydrolysis and other heat-catalyzed degradation reactions at any particular time point in the life of a CSP represents the thermodynamic sum of exposure temperatures and durations.
Such lifetime stability exposure is represented in the mean kinetic temperature calculation see Pharmaceutical Calculations in Prescription Compounding Drug hydrolysis rates increase exponentially with arithmetic temperature increase; thus, exposure of a beta-lactam antibiotic solution for one day at controlled room temperature see General Notices and Requirements will have an equivalent effect on the extent of hydrolysis of approximately 3 to 5 days in cold temperatures see General Notices and Requirements.
Personnel who prepare, dispense, and administer CSPs must store them strictly in accordance with the conditions stated on the label of ingredient products and finished CSPs. When CSPs are known to have been exposed to temperatures warmer than the warmest labeled limit, but not exceeding 40 see General Notices and Requirements for more than 4 hours, such CSPs should be discarded, unless appropriate documentation or direct assay data confirms their continued stability.
Determining Beyond-Use Dates. When CSPs deviate from conditions in the approved labeling of manufactured products contained in CSPs, compounding personnel may consult the manufacturer of particular products for advice on assigning beyond-use dates based on chemical and physical stability parameters. Beyond-use dates for CSPs that are prepared strictly in accordance with manufacturers’ product labeling must be those specified in that labeling, or from appropriate literature sources or direct testing.
In addition, the pharmacist may refer to applicable publications to obtain relevant stability, compatibility, and degradation information regarding the drug or its congeners. When assigning a beyond-use date, pharmacists should consult and apply drug-specific and general stability documentation and literature where available, and they should consider the nature of drug and its degradation mechanism, the container in which it is packaged, the expected storage conditions, and the intended duration of therapy see Expiration Date and Beyond-Use Date under Labeling in the General Notices and Requirements.
Compounding FAQ for veterinarians
Compounding is an integral part of pharmacy practice and is essential to the provision of health care. Compounders must be familiar with statutes and regulations that govern compounding because these requirements vary from state to state. The compounder is responsible for compounding preparations of acceptable strength, quality, and purity with appropriate packaging and labeling in accordance with good compounding practices see Good Compounding Practices , official standards, and relevant scientific data and information.
Compounders engaging in compounding should have to continually expand their compounding knowledge by participating in seminars, studying appropriate literature, and consulting colleagues. The compounder is responsible for ensuring that the quality is built into the compounded preparations of products, with key factors including at least the following general principles.
See also Good Compounding Practices
Pharmacists are required to affix beyond- use dates and not expiration dates to the prescription or repackaged vial. The definition of a beyond-use date may be.
The chapter was to have become official on December 1, , but USP-NF announced on September 23, , that appeals were pending on provisions of the chapter regarding beyond-use dating, use of alternative technologies proven equivalent to those described in the chapter, and applicability of the chapter to veterinary practitioners.
This notice and content of this program will be updated as events occur. Compounding has been a fundamental aspect of providing medicines to patients for centuries. Physicians, chemists, and pharmacists manipulated naturally derived products including those of plant, mineral, and animal origin into medicines. They did this through mixing, grinding, filtering, percolating, heating, and distilling, which led to preparations of vinegars, extracts, infusions, elixirs, syrups, tinctures, ointments, and pills.
Today, compounding has made a resurgence because of many drug shortages in recent years; the need for customized drug formulations as a result of allergies; special dosage forms for pediatric patients, geriatric patients, and special needs populations; and the movement toward specialty and personalized medicines. Sterile preparations typically include injections, infusions, irrigations, ophthalmic, and inhalation preparations.
Nonsterile preparations typically include oral suspensions, topical solutions, topical suspensions, topical gels, powders, ointments, creams, emulsions, and suppositories. The U. For the convenience of those studying this program, the numerous acronyms used are compiled in Table 1.
USP Finalizes Revisions to Sterile Compounding Standards
General notices and closures. Name according to usp underwent new revisions as of july At mcguff compounding. An updated draft of providing medicines to meet current needs and requirements. New product categories of csps has been laid out in , First published june 1: compounding — sterile preparations.
“Beyond Use Date” refers to the date placed on a prescription label that is “Compounder or Compounding Personnel” is the pharmacist or other licensed.
To support compounding of products that are sterile and chemically stable, beyond use dating of admixtures must include a thorough evaluation of appropriate resources. In most instances, resources provide documentation of a specific compounded admixture, at a specific concentration and storage parameters, that does not coincide with current operations or patient-specific requirements.
To meet the operational demands of a pharmacy, institutions employ a referenced guideline approach to guide decision making for safe sterile admixing. Often these guidelines are established and maintained at individual practicing locations with varying levels of detail and accuracy. In an effort to improve sterile compounding across a multihospital system, we developed and implemented beyond use dating guidelines to improve consistency and patient safety while meeting regulatory concerns.
Beyond use date BUD is the date after which a compounded preparation shall not be used, and it is set based on the date on which the preparation was compounded. To support compounding of products that are both sterile and chemically stable, beyond use dating of sterile compounded admixtures must include a thorough evaluation of appropriate resources.
Prior to admixing, literature should be evaluated to determine the chemical stability of each medication at a referenced concentration range, within a specified diluent, and stored at appropriate temperature within an appropriate container. The chemical stability must also be cross-referenced with current US Pharmacopeial Convention standards to ensure that sterility is maintained throughout the storage period.
It is important to note that BUDs and expiration dates are not the same. Beyond use dating applies the same expiration dating principles, but adds the consideration of sterility. Each category differs in the potential for microbial contamination during the compounding of the admixture.
Stability of Drug
To ensure that compounded preparations are made and used safely, published data and suitable testing must be considered. This BUD Databank provides the results of our stability-indicating studies, using our line of dye-free oral vehicles. Through strategic partnerships with renowned institutions, we offer a wide variety of stability data tested in various dispensers and container closures , using both forms of APIs : pure powder and commercial drugs. The databank below releases the results of some of our published studies.
Do you have the beyond-use date (BUD) and relevant stability data? • Do you have a dedicated space for compounding that is clean and uncluttered? • Do you.
The information presented herein reflects the opinions of the contributors and advisors. It should not be interpreted as an official policy of ASHP or as an endorsement of any product. Because of ongoing research and improvements in technology, the information and its applications contained in this text are constantly evolving and are subject to the professional judgment and interpretation of the practitioner due to the uniqueness of a clinical situation.
The editors and ASHP have made reasonable efforts to ensure the accuracy and appropriateness of the information presented in this document. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without written permission from the American Society of Health-System Pharmacists. Patent and Trademark Office.
It is impossible to recognize and thank you all appropriately for your continued support of this ongoing drug information project. The preparation of this updated reference was a team effort that would not have been possible without the exceptional group of capable writers and reviewers. They spent many hours on what some might consider minutia but this team considers essential.
Viewpoint: Should an RX label require a use-by date or an expiration date?
Whereas, The deferred operation of this act would tend to defeat its purpose, which is to enhance forthwith the safety of drug compounding in the commonwealth, therefore, it is hereby declared to be an emergency law, necessary for the immediate preservation of the public health. Monetary penalties collected shall be held separately and used by the commissioner in accordance with the requirements of said section 42D.
The governor shall appoint 13 members to the board.
Beyond use date. A pharmacy quality assurance commission. Compounding. With proper labeling. Official december 1, official december ; becomes.
Note: certain features of this site have been disabled for the general public to prevent digital piracy. You agree not to use any web crawler, scraper, or other robot or automated program or device to obtain data from the website. You agree that you will not sell or license anything that you download, print, or copy from this website. In the case where a quantity of compounded drug preparation is in excess of that to be initially dispensed is prepared, the excess preparation shall be labeled or documentation referenced with the complete list of ingredients components , the preparation date, and the assigned beyond-use date based upon the pharmacist’s professional judgment, appropriate testing, or published data.
It shall also be stored and accounted for under conditions dictated by its composition and stability characteristics e. The requirements of this chapter do no apply to the compounding or mixing of FDA-approved drugs preparations pursuant to the manufacturer’s directions for dispensing including but not limited to the reconstitution of oral suspensions, combination of the components of topical preparations, etc. R oute : S earch tips. Compounding also includes the preparation of drugs or devices in anticipation of prescription drug orders based on routine and regularly observed prescribing patterns.
Compounding does not include mixing, reconstituting, or similar acts that are performed in accordance with the directions contained in approved labeling provided by the product’s manufacturer and other manufacturer directions consistent with that labeling. Known allergies; 2. Rational therapy-contraindications; 3. Reasonable dose and route of administration; and 4.
Reasonable directions for use.